Walter F. Stewart
Walter F. Stewart has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Richard B. Lipton
The Saul R. Korey Department of Neurology Albert Einstein College of Medicine Bronx New York USA
2 shared publications - Cao Xiao
GE Healthcare, Bellevue, WA, USA
1 shared publication - David Gomez-Ulloa
Instituto Grifols SA, Global HEOR & RWE, Sant Cugat del Vallès, Spain
1 shared publication - Dylan S. Small
Department of Statistics and Data Science, University of Pennsylvania , 265 South 37th Street , Philadelphia, Pennsylvania 19104
1 shared publication - James Brian Jones
Sutter Health Research Institute, 2121 North California Blvd., Suite 310, Walnut Creek, CA 94596, USA
1 shared publication - Jason Roy
Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Rutgers University, Piscataway, NJ, USA
1 shared publication
Latest Publications
- 1 May 2024
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 21 (5) , 353-365
Post-Hoc Assessment of Cognitive Efficacy in Alzheimer’s Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled Trial
Background: Disease progression in Alzheimer’s Dementia (AD) is typically characterized by accelerated cognitive and functional decline, where heterogeneous trajectories can impact the observed treatment response. Methods: We hypothesized that unobserved heterogeneity could obscure treatment benefits in AD. The effect of unobserved heterogeneity was empirically quantified within the Alzheimer’s Management By Albumin Replacement (AMBAR) phase 2b trial data. The ADAS-Cog 12 cognition endpoint was reanalyzed in a 2-class latent growth mixture model initially fit to the treatment arm. The model with the best fit was then applied across both treatment arms to a larger (n=1000) simulated dataset that was representative of AMBAR trial cognitive data. Results: Two classes of patients were observed: a stable cognitive trajectory class and a highly variable class. Removal of the latter (n=48, 22%) from the analysis and refitting efficacy models comparing the stable class to full placebo yielded significant treatment efficacy on cognition (p=0.007, Cohen’s D=-0.4). Comparison of the stable class of each arm within the simulated dataset revealed a significant difference in treatment efficacy favoring the simulated stable treatment arm. Conclusion: This post hoc exploratory analysis suggests that prespecified strategies for addressing unobserved heterogeneity may yield improved effect detection in AD trials. The generalizability of the analytic strategy is limited by latent stratification in only the treatment arm, a requirement given the small placebo arm in AMBAR. This limitation was partially addressed by the simulation modeling. Clinical Trial Registration Number:: NCT01561053
- 1 May 2024
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 21 (5) , 353-365
Post-Hoc Assessment of Cognitive Efficacy in Alzheimer’s Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled Trial
Background: Disease progression in Alzheimer’s Dementia (AD) is typically characterized by accelerated cognitive and functional decline, where heterogeneous trajectories can impact the observed treatment response. Methods: We hypothesized that unobserved heterogeneity could obscure treatment benefits in AD. The effect of unobserved heterogeneity was empirically quantified within the Alzheimer’s Management By Albumin Replacement (AMBAR) phase 2b trial data. The ADAS-Cog 12 cognition endpoint was reanalyzed in a 2-class latent growth mixture model initially fit to the treatment arm. The model with the best fit was then applied across both treatment arms to a larger (n=1000) simulated dataset that was representative of AMBAR trial cognitive data. Results: Two classes of patients were observed: a stable cognitive trajectory class and a highly variable class. Removal of the latter (n=48, 22%) from the analysis and refitting efficacy models comparing the stable class to full placebo yielded significant treatment efficacy on cognition (p=0.007, Cohen’s D=-0.4). Comparison of the stable class of each arm within the simulated dataset revealed a significant difference in treatment efficacy favoring the simulated stable treatment arm. Conclusion: This post hoc exploratory analysis suggests that prespecified strategies for addressing unobserved heterogeneity may yield improved effect detection in AD trials. The generalizability of the analytic strategy is limited by latent stratification in only the treatment arm, a requirement given the small placebo arm in AMBAR. This limitation was partially addressed by the simulation modeling. Clinical Trial Registration Number:: NCT01561053
- Open Access
- 13 May 2019
- Published by Association for Computing Machinery (ACM)
- p. 2558-2564
Longitudinal Adversarial Attack on Electronic Health Records Data
- 13 May 2019
- Published by Association for Computing Machinery (ACM)
- p. 2558-2564
Open AccessLongitudinal Adversarial Attack on Electronic Health Records Data
- Open Access
- 20 February 2015
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 17 (2) , e42
The Wired Patient: Patterns of Electronic Patient Portal Use Among Patients With Cardiac Disease or Diabetes
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
- 20 February 2015
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 17 (2) , e42
Open AccessThe Wired Patient: Patterns of Electronic Patient Portal Use Among Patients With Cardiac Disease or Diabetes
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
- Open Access
- 1 December 2013
- Published by Ubiquity Press, Ltd. in eGEMs (Generating Evidence & Methods to improve patient outcomes)
- Vol. 1 (3) , 1040
Methods for Estimating Kidney Disease Stage Transition Probabilities Using Electronic Medical Records
Chronic diseases are often described by stages of severity. Clinical decisions about what to do are influenced by the stage, whether a patient is progressing, and the rate of progression. For chronic kidney disease (CKD), relatively little is known about the transition rates between stages. To address this, we used electronic health records (EHR) data on a large primary care population, which should have the advantage of having both sufficient follow-up time and sample size to reliably estimate transition rates for CKD. However, EHR data have some features that threaten the validity of any analysis. In particular, the timing and frequency of labratory values and clinical measurements are not determined a priori by research investigators, but rather, depend on many factors, including the current health of the patient. We developed an approach for estimatating CKD stage transition rates using hidden Markov models (HMMs), when the level of information and observation time vary among individuals. To estimate the HMMs in a computationally manageable way, we used a “discretization” method to transform daily data into intervals of 30 days, 90 days, or 180 days. We assessed the accuracy and computation time of this method via simulation studies. We also used simulations to study the effect of informative observation times on the estimated transition rates. Our simulation results showed good performance of the method, even when missing data are non-ignorable. We applied the methods to EHR data from over 60,000 primary care patients who have chronic kidney disease (stage 2 and above). We estimated transition rates between six underlying disease states. The results were similar for men and women.
- 1 December 2013
- Published by Ubiquity Press, Ltd. in eGEMs (Generating Evidence & Methods to improve patient outcomes)
- Vol. 1 (3) , 1040
Open AccessMethods for Estimating Kidney Disease Stage Transition Probabilities Using Electronic Medical Records
Chronic diseases are often described by stages of severity. Clinical decisions about what to do are influenced by the stage, whether a patient is progressing, and the rate of progression. For chronic kidney disease (CKD), relatively little is known about the transition rates between stages. To address this, we used electronic health records (EHR) data on a large primary care population, which should have the advantage of having both sufficient follow-up time and sample size to reliably estimate transition rates for CKD. However, EHR data have some features that threaten the validity of any analysis. In particular, the timing and frequency of labratory values and clinical measurements are not determined a priori by research investigators, but rather, depend on many factors, including the current health of the patient. We developed an approach for estimatating CKD stage transition rates using hidden Markov models (HMMs), when the level of information and observation time vary among individuals. To estimate the HMMs in a computationally manageable way, we used a “discretization” method to transform daily data into intervals of 30 days, 90 days, or 180 days. We assessed the accuracy and computation time of this method via simulation studies. We also used simulations to study the effect of informative observation times on the estimated transition rates. Our simulation results showed good performance of the method, even when missing data are non-ignorable. We applied the methods to EHR data from over 60,000 primary care patients who have chronic kidney disease (stage 2 and above). We estimated transition rates between six underlying disease states. The results were similar for men and women.
- 1 January 2001
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 109 (1) , 38-45
Migraine's impact today
Migraine is a common disorder that causes severe headaches and associated nausea, photophobia, phonophobia, and temporary disability. Though the pain and other symptoms of migraine can be effectively man' aged, the condition remains underdiagnosed and undertreated. In this article, Drs Lipton, Stewart, Reed, and Diamond consider the scope and distribution of the migraine problem and the current patterns of care in the United States.
- 1 January 2001
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 109 (1) , 38-45
Migraine's impact today
Migraine is a common disorder that causes severe headaches and associated nausea, photophobia, phonophobia, and temporary disability. Though the pain and other symptoms of migraine can be effectively man' aged, the condition remains underdiagnosed and undertreated. In this article, Drs Lipton, Stewart, Reed, and Diamond consider the scope and distribution of the migraine problem and the current patterns of care in the United States.